Skip to Content

Regeneron Pharmaceuticals Inc REGN Stock Quote

| Rating as of


Last close prices updated as of Feb 07, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 769.94
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Large Blend
  • Day Range 763.15  –  778.05
  • Year Range 538.01  –  800.48
  • Market Cap 84.1741 Bil
  • Volume / Avg 885,937.0 /  655,047.7
  • Price / Sales 7.18
  • Price / Book 3.71
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis REGN

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Maintaining Our $690 Regeneron Fair Value Estimate Following Q4 as We Await Pipeline Advancement

Karen Andersen Sector Strategist

Analyst Note

| Karen Andersen |

We’re maintaining our $690 fair value estimate for Regeneron following fourth-quarter results that were in line with our expectations, apart from significant one-time revenue from a large order for COVID-19 antibody Ronapreve in Japan. While we’ve added a placeholder for potential future COVID-19 antibody revenue to our model (to account for a next-generation product entering development this year) and slightly boosted our long-term sales assumptions for immunology drug Dupixent with additional pipeline progress, we’ve also increased our operating expense estimate to account for Regeneron’s continuing push into larger oncology clinical trials and more investment in the launch of Libtayo. We think the shares are slightly overvalued at recent prices, although we’re carefully watching for upcoming catalysts—like data for Dupixent in the large indication of chronic obstructive pulmonary disease and progress with novel CRISPR-based drug candidates like NTLA-2001 (partnered with Intellia)—for potential upside to our valuation. We continue to see Regeneron’s established presence in ophthalmology, steady Dupixent growth, and advancing oncology pipeline as supporting a narrow moat.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics REGN

Company Profile REGN

Business Description

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

777 Old Saw Mill River Road
Tarrytown, NY, 10591-6707
Industry Biotechnology
Employees 11,851

Related Articles REGN

FAQs for Regeneron Pharmaceuticals Inc Stock

No. REGN does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

REGN’s market cap is 84.17 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

REGN’s stock style is Large Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

REGN’s price/sales is 7.28.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

REGN’s price/forward earnings is 18.35.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

REGN’s price/book is 3.71.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See REGN’s valuation ratios compared to the Market Index.

REGN’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare REGN’s historical performance against its industry peers and the overall market.